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Concise asymmetric syntheses of novel phenanthroquinolizidines  
Cintia Anton-Torrecillas,
a
 María Isabel Loza,
b
 and José Brea
b 
and Jose C. Gonzalez-Gomez*
a 
The first preparation of enantioenriched phenanthroquinolizidines with a quaternary center at C14a was accomplished in 
seven steps from readily available starting materials. Key steps were an efficient dynamic kinetic allylation of a 
diastereomeric mixture of chiral tert-butylsulfinyl ketimines and the construction of piperidine E ring by rhodium catalyzed 
hydroformylation. The Stevens rearrangement of the corresponding N-benzyl derivatives took place smoothly, allowing 
the installation of a benzyl moiety at C9 in a trans relationship with the methyl group. The cytoxycity of the prepared 
phenanthroquinolizidines was evaluated against different human cancer cell lines. 
Introduction 
Compared with synthetic drugs, natural product derivatives 
show lower toxicity and easier decomposition, which is also 
more environmentally friendly.
1
 These advantages, in addition 
to their unique mode of action, are responsible for the 
growing interest in the synthesis and biological evaluation of 
natural based compounds. Among natural alkaloids are a small 
group of phenanthroquinolizidines (e.g. cryptopleurine and 
boehmeriasin A in Figure 1) which are produced by the 
Lauraceae, Vitaceae, and Urticaceae family of plants.
2
 
Remarkably, these compounds exhibit very high cytotoxic 
activities with IC50 in the nanomolar range, being in some cases 
more potent than taxol.
3
 Moreover, they have shown higher 
antiproliferative activity than their structurally related 
phenanthroindolizidine alkaloids.
4
 It is reported that these 
alkaloids and their analogs display a wide range of biological 
activities and they are currently being used as lead compounds 
in order to optimize these activities.
5 
Some natural phenanthroindolizidine alkaloids bearing a 
methyl group at the 13a-position (e.g. hypoestestatin 1 and 2, 
Figure 1) have been identified as extremely potent antitumor 
agents.
6
 Recent studies have shown that the inclusion of a 
substituent next to the nitrogen atom disrupts the molecular  
 
Fig.1 Some phenantroizidine alkaloids 
planarity, decreasing the crystal packing energy and therefore 
increasing their water solubility.
7
 It is worth to mention that 
enhance the hydrophilicity of these compounds is an 
established strategy to improve their bioavailability, so as to 
lower their blood-brain barrier permeability, which potentially 
might minimize their CNS toxicity.
8
 In this context, the 
asymmetric syntheses of some 13a-substituted 
phenanthroindolizidine alkaloids have been successfully 
accomplished, using proline derivatives as chiral building 
blocks.
9
 However, to our best knowledge, the enantioselective 
synthesis of structurally related phenanthroquinolizidines with 
a quaternary center at C14a remains unexplored. Given the 
unique biological activities of 7-methoxycryptopleurine,
10
 we 
considered that this compound would offers a good platform 
to explore this strategy.  
Results and discussion 
We describe herein a protocol for the asymmetric preparation 
of 7-(R)-and (S)-methoxy-14a-methylcryptopleurine,
11,12
 as 
well as the first regio- and diastereoselective Stevens 
rearrangement of the corresponding N-benzyl ammonium salt.  
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Scheme 1 Retrosynthetic analysis of the target molecule. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2 Syntheses of phenanthroquinolizidines 8 and ent-8. 
 
In our retrosynthetic analysis (Scheme 1), we envisaged that a 
benzyl group could be diastereoselectively installed at C-9 by 
N-benzylation of the corresponding phenanthroquinolizidine, 
followed by Stevens rearrangement. The synthesis of this 
scaffold was planned by building ring D in the last step using 
Pictet-Spengler annulation, while ring E could be formed by 
hydroformylation of the corresponding homoallylic amine.
13
 
Importantly, the chiral quaternary center was anticipated to be 
formed by allylation of the chiral tert-butylsulfinyl ketimine 
derived from the corresponding methylketone. As outlined in 
Scheme 1, the target molecule was traced back to: 9-bromo-
2,3,6,7-tetramethoxyphenanthrene, chiral tert-
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butylsulfinamide, allylindium reagent, formaldehyde and 
isoprenylacetate; all of them commercially or easily available 
starting materials.  
The realization of our synthetic plan is outlined in Scheme 2. 
The palladium catalyzed cross coupling of isoprenyl acetate 
with the readily available 9-bromo-2,3,6,7-
tetramethoxyphenanthrene
14
 was efficiently promoted by 
tributyltin methoxide to afford the desired methylketone 2 in 
high yield.
15
 Condensation of ketone 2 with (Ss)-tert-
butylsulfinamide afforded the corresponding ketimine as a 4:1 
mixture of E/Z isomers-3, which upon addition of in-situ 
formed allylindium reagent furnished the expected chiral 
amine 4 with an -quaternary center as a single isomer (>98:2 
dr according to NMR).
16
 This efficient dynamic kinetic 
transformation of tert-butylsulfinyl ketimines to homoallylic 
amines has been previously reported
17,18
 and it is worth 
mentioning that the one-pot indium mediated direct 
aminoallylation of the methyl ketone- a procedure that we 
have previously developed and successfully used in our 
group
19
- gave significantly lower conversion in this case (up to 
30 %). Our next key step was the rhodium catalyzed linear 
hydroformylation to build ring E as an enamine. Given our 
previous experience with this strategy,
13
 the sulfinyl group was 
replaced by an N-Boc protecting group. We thus submitted 
compound 5 to rhodium(I) catalyzed hydroformylation with 
formalin, using two different phosphane ligands (BIPHEP and 
NiXantphos). The characteristics of this hydroformylation 
protocol are unique because the syngas (CO/H2) is 
conveniently substituted by formaldehyde, with excellent 
linear selectivity.
20
 Under these conditions, the formation of 
the corresponding terminal aldehyde was followed by in-situ 
cyclization to furnish the protected enamine 6. We were 
pleased to observe that by only increasing the loading of 
rhodium catalyst from 1 mol % to 3 mol %, the isolated yield of 
compound 6 increased from 61% to 90%. Catalytic 
hydrogenation of enamine 6 using Adams’s catalyst, followed 
by acidic removal of the Boc group and Pictet Spengler 
cyclomethylenation under standard conditions (formalin, HCl, 
EtOH, 100 ºC),
21
 allowed the preparation of the target 
compound 8 with very good overall yield. The same synthetic 
sequence was applied to obtain ent-8 from (Rs)-tert-
butylsulfinamide with similar efficiency in terms of isolated 
yields. Chiral HPLC analysis of both enantiomers (8 and ent-8) 
shows that racemization did not take place over the synthetic 
sequence (96:4 er, see ESI). 
During the optimization of the biological activities of 
phenanthroquinolizidines, diverse substituted compounds 
have been reported in the literature.
4b,
 
10d, 22
 However, 
substitutions at C-9 of this skeleton remain scarce.
23
 With this 
in mind, we decided to explore the Stevens rearrangement
24
 of 
the N-benzyl isoquinolinium salts 9 and ent-9, which were 
efficiently prepared using conventional methods (Scheme 3). It 
is worth noting that the NMR data (
1
H and 
13
C) obtained for 
these compounds is consistent with a single diastereoisomer. 
In contrast with other related alkaloids that contains the 
quinolizidine moiety (e.g. berbines),
25
 inversion at the N 
bridgehead of the starting material is unlikely in phenanthro- 
 
Scheme 3 Regio-and Stereoselective Stevens Rearrangement of compound 9 
quinolizidines and the adjacent methyl group should stabilize 
the trans isomer. It is generally assumed that, either by 
formation of an iminium ion or via recombination of radical 
pairs in solvent-cage,
26
 the Stevens rearrangement is 
suprafacial. Given that only trans-isoquinolinium isomer 9 
seems to be present, deprotonation at the benzylic C-9 
position, followed by the rearrangement should only afford 
trans-10 compound. Given the good results obtained in the 
synthesis of 8-benzylberbines, by using in-situ prepared dimsyl 
sodium solution at room temperature for the Stevens 
rearrangement, we adopted these conditions and compound 
10 was obtained in a moderate yield.
 27
 Although we were not 
able to identify the by-products formed in this reaction, we 
reasoned that hydrogens at β-positions (H12eq, H14eq and H15eq) 
make Hofmann eliminations competitive pathways. 
Importantly, a significant H,H-n.O.e was observed between the 
Me at C14a and H9 of compound 10 (see SI), confirming the 
presumed trans-configuration for this compound. Using the 
same method, ent-9 was transformed into ent-10. Having 
prepared both enantiomers, the enantiomeric purity of the 
samples was determined by chiral HPLC analysis, being above 
90% ee in both cases. 
Compounds 8, 9, 10 and their enantiomers were tested against 
four human cancer cell lines, using the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5- diphenyltretrazolium bromide) 
method and CDDP [cis-diaminedichloroplatinum (II)] as 
positive control. The IC50 values were determined from the 
corresponding inhibition/concentration curves (see SI) when 
more than 50% cellular growth inhibition was achieved at 100 
M and the results are shown in Table 1. The best results were 
obtained for compound 8, with the (R)-configuration (as in 
natural cryptopleurine), against human breast cancer cell lines 
(MCF-7) and with leukemia cells (HL-60). The potency of this 
compound was 20-fold (for MCF-7) or 10-fold (for HL-60) 
superior to that its enantiomer, but it was significantly lower 
than the one of the (R)-7-methoxycryptopleurine, without a 
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methyl group at C14a.
13
 Unfortunately, when the benzyl group 
was attached to the nitrogen atom and then rearranged to C9, 
the obtained compounds showed poorer cellular growth 
inhibition. 
Table 1 Cytotoxicity of compounds evaluated. 
 
Compounds 
IC50 ( M)a 
MCF-7b NCI-H460c HL-60d NCI/ADR-RESe 
CDDP 16 ± 1 5.7 ± 0.2 8.3 ± 0.2 6.3 ± 0.2 
8·HCl 1.1 ± 0.1 34f ± 7 0.51 ±0.02 69f ± 26 
ent-8·HCl 21 ± 2 42 ± 1 4.9 ± 0.1 26 ± 1 
9 80f ± 14 n.dg 65f ± 5 n.dg 
ent-9 76f ± 7 393f ± 168 n.dg n.dg 
10 35f ± 1 n.dg 80f±3 n.dg 
ent-10 36 ± 1 n.dg n.dg n.dg 
a Average of three assays each. b MCF-7 = human breast carcinoma. c NCI-H460 = 
human lung carcinoma. d HL-60 = human promyelocytic leukemia. e NCI-ADR-RES= 
drug-resistant human ovarian adenocarcinoma. f Extrapolated values from an 
incomplete concentration-response curve (see SI). g Not determined. 
Conclusions 
We have developed a seven step procedure to prepare 
enantioenriched 14a-methyl-7-methoxycryptopleurine in 18-
21% overall yield from readily available starting materials. 
Salient features of the synthetic procedure are: (a) the 
straightforward formation of methyl ketone 2; (b) the efficient 
dynamic kinetic allylation of tert-butylsulfinyl ketimines 3 (4:1 
E/Z mixture) to obtain compound 4 as a single isomer; and (c) 
a rhodium catalyzed linear hydroformylation with formalin 
that allows construction of ring E in excellent yield. N-
benzylation of phenanthroquinolizidine 8, followed by Stevens 
rearrangement at room temperature allows for regio- and 
stereoselective placement of a benzyl group and C9. The 
cytotoxic evaluation of compound 8 (ent-8) indicates that the 
introduction of a methyl group at C14a decreases the potency 
of 7-methoxycryptopleurine. In addition, the introduction of a 
benzyl group at C9 of the same scaffold had a more significant 
negative impact on its cytotoxicity. The synthetic route 
developed herein opens the access to enantioenriched 
phenathroquinolizidines with a quaternary center at C14a and 
trans-C9 benzyllic derivatives, which hopefully can display 
different biological activities. 
Experimental 
General information 
TLC was performed on silica gel 60 F254, using aluminium plates 
and visualized by exposure to ultraviolet light. Flash 
chromatography was carried out on handpacked columns of 
silica gel 60 (230 − 400 mesh). Optical rotations were 
measured using a polarimeter with a thermally jacketted 5 cm 
cell at approximately 20 ºC and concentrations (c) are given in 
g/100 mL. Infrared analysis was performed with a 
spectrophotometer equipped with an ATR component; 
wavenumbers are given in cm
-1
. HRMS analyses were carried 
out using the Electron Impact (EI) mode at 70 eV or by Q-TOF 
using Electro Spray Ionization (ESI) mode. HPLC analyses were 
performed using a Chiralpak IB column for enantiomeric ratios.
 
1
H NMR spectra were recorded at 300 or 400 MHz for 
1
H NMR 
and 75 or 100 MHz for 
13
C NMR, using CDCl3 as the solvent and 
TMS as an internal Standard (0.00 ppm). 
13
C NMR spectra were 
recorded with 
1
H-decoupling at 100 MHz and referenced to 
CDCl3 at 77.16 ppm. DEPT-135 experiments were performed to 
assign CH, CH2 and CH3. 
1-(2,3,6,7-tetramethoxyphenanthren-9-yl)propan-2-one (2). A 
dry flask was charged with 9-bromo-2,3,6,7-
tetramethoxyphenanthrene
14
 (391 mg, 1.04 mmol), Pd(OAc)2 
(11.67 mg, 0.05 mmol, 5 mol %) and tri-ortho-tolylphosphine 
(33 mg, 0.10 mmol). The reaction mixture was evacuated and 
backfilled with argon (3 cycles) before adding toluene (1.21 
mL), tributyltin methoxide (463 L, 1.60 mmol) and isoprenyl 
acetate (174 L, 1.57 mmol). The reaction mixture was stirred 
while heating at 100 ºC during 6 h. The reaction mixture was 
cooled down to room temperature and diluted with EtOAc (2.0 
mL) and 4 M aqueous potassium fluoride solution (1.5 mL) and 
stirred for 15 min, before being filtered through a short pad of 
Celite, washed with EtOAc and concentrated under vacuo. The 
residue was purified by flash chromatography (6:4 to 1:1 
hexane/EtOAc), recovering the starting material (98 mg, 25%) 
and obtaining the desired product as a ochre yellow solid (274 
mg, 74%): Rf 0.24 (1:1 hexane/EtOAc);
 1
H NMR (300 MHz, 
CDCl3) δ 7.83 (s, 1H), 7.78 (s, 1H), 7.53 (s, 1H), 7.28 (s, 1H), 7.21 
(s, 1H), 4.12 (s, 3H), 4.12 (s, 3H), 4.06 (s, 2H), 4.04 (s, 3H), 4.02 
(s, 3H), 2.09 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 208.0 (C), 
149.5 (C), 149.2 (C), 149.1 (C), 127.3 (C), 126.6 (CH), 126.34 (C), 
125.6 (C), 125.1 (C), 124.4 (C), 108.2 (CH), 105.1 (CH), 103.5 
(CH), 102.9 (CH), 56.2 (CH3), 56.19 (CH3), 56.0 (CH3), 50.8 (CH2), 
28.7 (CH3); HRMS (ESI) calcd for C21H23O5  355.1545, found 
355.1549. 
(E/Z,SS)-N-(tert-Butylsulfinyl)-1-(2,3,6,7-tetramethoxy-
phenanthren-9-yl)propan-2-imine (3). To a dry flask were 
sequentially added (SS)- tert-butylsulfinamide (1.83 mg, 1.50 
mmol), compound 2 (531 mg, 1.5 mmol) and THF (3.0 mL), 
followed by Ti(OEt)4  (675 µL, 3.0 mmol). The reaction mixture 
was stirred overnight at 65 ºC. After cooled to room 
temperature, it was carefully added over a stirring mixture of 
4:1 EtOAc/brine. The resulted white suspension was filtered 
through a short pad of Celite, washed with EtOAc and 
concentrated to dryness. The residue was purified by flash 
chromatography (4:6 to 3:7 hexane/EtOAc,), affording the 
imine as a yellow foam solid (401 mg, 76%, 80:20 E/Z): 
 
Rf 0.23 
(3:7 hexane/EtOAc);
  1
H NMR (300 MHz, CDCl3) δ 7.83 (s, 1H), 
7.78 (s, 1H), 7.55 – 7.48 (m, 1H), 7.47 – 7.42 (m, 1H), 7.23 – 
7.19 (m, 1H), 4.13 (s, 6H), 4.04 (s, 3H), 4.02 (s, 3H), 2.29 (s, 
1.84H, E-isomer), 2.09 (s, 0.36H, Z-isomer), 1.23 (s, 1.31H, Z-
isomer), 1.20 (s, 5.69H, E-isomer); 
13
C NMR (75 MHz, CDCl3) δ 
149.5 (C), 149.2 (C), 149.1 (C), 149.0 (C), 128.1 (C), 126.6, 126.2 
(C), 125.8 (C), 125.1 (C), 124.4 (C), 108.2 (CH), 105.6 (CH), 
103.5 (CH), 102.9 (CH), 56.6 (C), 56.3 (2CH3), 56.2 (CH3), 56.1 
(CH3), 49.3 (CH2), 22.3 (CH3), 21.8 (CH3); HRMS (ESI) calcd for 
C25H31NO5NaS  480.1821, found 480.1827. 
(ent-3). It was prepared from (RS)- tert-butylsulfinamide (228.7 
mg, 1.89 mmol), following the same procedure described for 
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the preparation of 3, with similar yield (571 mg, 66 %). It was 
obtained as a 4:1 E/Z mixture with identical characterization 
data than compound 3. 
(1R,SS)-N-(tert-Butylsulfinyl)-1-allyl-1-methyl-2-[2,3,6,7-
tetramethoxyphenanthren-9-yl]-ethylamine (4). To a mixture 
of imine 3 (505 mg, 1.10 mmol) in dry THF (2.2 mL) were 
sequentially added indium powder (159 mg, 1.38 mmol) and 
allyl bromide (144 L, 1.66 mmol). The reaction mixture was 
stirred overnight under argon atmosphere at 65 ºC. 
Afterwards, the mixture was filtered through a short pad of 
Celite, washed with EtOAc and concentrated. The residue was 
purified by flash chromatography (hexane/EtOAc 3:7) to obtain 
the desired product as a white amorphous solid (398 mg, 72%, 
>98:2 dr according to 
1
H-NMR
16
): [α]
D
20 −3.0 (c 6.56, CHCl3); Rf 
0.18 (3:7 hexane/EtOAc); 
1
H NMR (300 MHz, CDCl3) δ 7.80 (s, 
1H), 7.74 (s, 1H), 7.60 (s, 1H), 7.43 (s, 1H), 7.18 (s, 1H), 6.09 – 
5.92 (m, 1H), 5.29 (d, J = 3.2 Hz, 1H), 5.23 (s, 1H), 4.11 (s, 3H), 
4.11 (s, 3H), 4.04 (s, 3H), 4.02 (s, 3H), 3.77 (s, 1H), 3.43 (d, J = 
14.2 Hz, 1H), 3.28 (d, J = 14.2 Hz, 1H), 2.66 (d, J = 7.3 Hz, 2H), 
1.23 (s, 3H), 1.07 (s, 9H); 
13
C NMR (75 MHz, CDCl3) δ 149.3 (C), 
149.1 (C), 148.9 (C), 148.6 (C), 133.7 (CH), 128.9 (C), 127.9, 
126.6 (C), 126.1 (C), 125.1 (C), 123.9 (C), 120.1 (C), 108.1 (CH), 
105.9 (CH), 103.5 (CH), 102.8 (CH), 59.4 (C), 56.8 (C), 56.3 
(2CH3), 56.2 (CH3), 56.1 (CH3), 46.0(CH2), 42.2 (CH2), 26.5 (CH3), 
22.8 (CH3); HRMS (ESI) calcd for C28H38NO5S 500.2471, found 
500.2478. 
(ent-4). It was prepared from ent-3 (925 mg, 2.02 mmol), 
following the same procedure described for the preparation of 
4, with better yield (819 mg, 81 %) and identical 
characterization data, except for the optical rotation: [α]D
20
 + 6 
(c 4.13, CHCl3). 
(2R)-tert-Butyl-(2-methyl-1-(2,3,6,7-tetramethoxy-
phenanthren-9-yl)pent-4-en-2-yl)carbamate (5). To a solution 
of compound 4 (313 mg, 0.76 mmol) in MeOH (7.6 mL) was 
added a solution of 4 M HCl in Dioxane (0.76 mL, 3.04 mmol) 
at 0 ºC. The reaction mixture was stirred 1.5 h at 25 ºC and 
then was concentrated to dryness. The residue was dissolved 
in CH2Cl2 (7.6 mL) and after cooled down the solution to 0 ºC, a 
2 M aqueous solution of NaOH (7.6 mL) and Boc2O (188.1 mg, 
0.84 mmol) were sequentially added. The mixture was stirred 
under argon atmosphere at 25 ºC during 2.5 h. The mixture 
was extracted with CH2Cl2 (3 x 20 mL), the collected organic 
layers were washed with brine (5 mL), dried over MgSO4 and 
concentrated to dryness. The crude product was purified by 
flash chromatography (7:3 hexane/EtOAc) to obtain the 
desired product as a white amorphous solid (286 mg, 76%): 
[α]D
20
 −18 (c 6.83, CHCl3); Rf  0.20 ( 7:3 hexane/EtOAc); 
1
H NMR 
(300 MHz, CDCl3) δ 7.82 (s, 1H), 7.78 (s, 1H), 7.71 (s, 1H), 7.43 
(s, 1H), 7.15 (s, 1H), 5.97 – 5.78 (m, 1H), 5.21 – 5.05 (m, 2H), 
4.44 (s, 1H), 4.13 (s, 3H), 4.12 (s, 3H), 4.09 (s, 3H), 4.02 (s, 3H), 
3.69 – 3.59 (m, 1H), 3.41 (d, J = 14.1 Hz, 1H), 2.87 (dd, J = 13.3, 
7.3 Hz, 1H), 2.34 (dd, J = 13.7, 7.4 Hz, 1H), 1.49 (s, J = 10.3 Hz, 
9H), 1.18 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 154.7 (C), 149.2 
(C), 148.9 (C), 148.8 (C), 148.5 (C), 134.1 (CH), 130.2 (C), 127.1 
(CH), 127.0 (C), 126.2 (C), 124.9 (C), 123.8 (C), 118.9 (CH2), 
108.0 (CH), 106.6 (CH), 103.2 (CH), 102.9 (CH), 78.9 (C), 56.4 
(CH3), 56.3 (CH3), 56.1 (CH3), 55.9 (CH3), 43.4 (CH2), 40.1 (CH2), 
28.7 (CH3), 25.3 (CH3); HRMS (ESI) calcd for C29H37NO6Na 
518.2519, found 518.2523. 
(ent-5). It was prepared from ent-4 (819 mg, 1.64 mmol), 
following the same procedure described for the preparation of 
5, with similar yield (568 mg, 70%) and identical 
characterization data, except for the optical rotation: [α]D
20
 + 
15 (c 7.50, CHCl3). 
(2R)-tert-Butyl-2-methyl-2-((2,3,6,7-tetramethoxy-
phenanthren-9-yl)methyl)-3,4-dihydropyridine-1(2H)-
carboxylate (6). To a pressure tube were sequentially added 
[RhCl(cod)]2 (6.92 mg, 0.014 mmol), BIPHEP (14.97 mg, 0.028 
mmol), NiXantphos (15.80 mg, 0.028 mmol) and toluene (2.8 
mL). The system was then evacuated and filled back with 
argon before compound 5 (232 mg, 0.468 mmol) and aqueous 
formalin (37%, 0.3 mL, 12.65 mmol) were added. The reaction 
mixture was deoxygenated via three cycles of freeze-pump 
and thaw under argon atmosphere and heated to 90 ºC. The 
mixture was stirred for 40 h at the same temperature and then 
left to reach room temperature, before being concentrated 
and purified by flash chromatography (hexane/EtOAc 7:3) to 
obtain the desired product as a white amorphous solid (213 
mg, 90 %): [α]D
20
 − 21 (c 6.86, CHCl3);  Rf  0.21 ( 7:3 
hexane/EtOAc); 
1
H NMR (300 MHz, CDCl3) δ 7.95 (s, 1H), 7.81 
(s, 1H), 7.78 (s, 1H), 7.37 (s, 1H), 7.16 (s, 1H), 6.93 (d, J = 8.6 Hz, 
1H), 5.00 – 4.91 (m, 1H), 4.14 (s, 3H), 4.12 (s, 3H), 4.12 (s, 3H), 
4.04 (s, 3H), 3.97 (s, 1H), 3.08 (d, J = 14.0 Hz, 1H), 2.45 – 2.27 
(m, 1H), 2.17 – 1.95 (m, 2H), 1.80 – 1.65 (m, 1H), 1.45 (s, 3H), 
1.26 (s, 9H); 
13
C NMR (75 MHz, CDCl3) δ 152.7 (C), 149.0 (C), 
148.9 (C), 148.8 (C), 148.6 (C), 131.0 (C), 127.5 (C), 127.4 (CH), 
126.6 (CH), 126.2 (C), 124.8 (C), 123.9 (C), 108.0 (CH), 107.1 
(CH), 104.3 (CH), 103.0 (CH), 102.9 (CH), 80.5 (C), 58.3 (C), 56.3 
(CH3), 56.2 (CH3), 56.1 (CH3), 56.0 (CH3), 37.6 (CH2), 35.9 (CH2), 
28.2 (CH3), 25.9 (CH3), 19.2 (CH2); HRMS (ESI) calcd for 
C30H37NO6Na 530.2519, found 530.2510. 
(ent-6). It was prepared from ent-5 (473 mg, 0.95 mmol), 
following the same procedure described for the preparation of 
6, with similar yield (353 mg, 82 %) and identical 
characterization data, except for the optical rotation: [α]D
20
 + 
27 (c 4.6, CHCl3). 
(R)-tert-Butyl-2-methyl-2-((2,3,6,7-
tetramethoxyphenanthren-9-yl)methyl)piperidine-1-
carboxylate (7). A dry flask was charged with compound 6 (93 
mg, 0.18 mmol), PtO2 (83% content Pt, 10.0 mg, 0.04 mmol) 
and a mixture of EtOH/AcOH (3.4 mL : 1.4 mL). The flask was 
connected to a balloon of hydrogen through a three-ways 
valve and the reaction mixture was put under hydrogen 
atmosphere (1 atm) after 3 cycles of freeze-pump and thaw. 
The resulting suspension was stirred at 25 °C for 24 h, and then 
was filtered throught Celite and washed with EtOAc (3 x 15 
mL). The organic solution was concentrated to dryness and the 
desired product was obtained as white amorphous solid (90 
mg, > 99%): [α]D
20
 16 (c 7.90, CHCl3); Rf 0.21 ( 7:3 
hexane/EtOAc); 
1
H NMR (300 MHz, CDCl3) δ 7.95 (s, 1H), 7.83 
(s, 1H), 7.79 (s, 1H), 7.38 (s, 1H), 7.15 (s, 1H), 4.13 (s, 6H), 4.12 
(s, 3H), 4.04 (s, 3H), 3.86 – 3.71 (m, 2H), 3.43 (d, J = 14.0 Hz, 
1H), 3.11 – 2.96 (m, 1H), 1.98 – 1.84 (m, 1H), 1.77 – 1.57 (m, 
4H) 1.48 (s, 13H); 
13
C NMR (75 MHz, CDCl3) δ 155.9 (C), 149.0 
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(C), 148.9 (C), 148.79 (C), 148.5 (C), 131.3 (C), 127.5 (C), 126.5 
(CH), 126.3 (C), 124.9 (C), 123.8 (C), 108.1 (CH), 107.3 (CH), 
103.1 (CH), 103.0 (CH), 79.3 (C), 59.2 (C), 56.3 (2CH3), 56.1 
(CH3), 56.0 (CH3), 41.4 (CH2), 38.2 (CH2), 35.6 (CH2), 28.7 (CH3), 
26.3 (CH3), 23.3 (CH2), 17.6 (CH2); HRMS (ESI) calcd for 
C30H39NO6Na 532.2675 found 532.2663. 
(ent-7). It was prepared from ent-6 (370 mg, 0.73 mmol), 
following the same procedure described for the preparation of 
7, with similar yield (568 mg, >99%) and identical 
characterization data, except for the optical rotation: [α]D
20
  
20 (c 2.42, CHCl3). 
(R)-2,3,6,7-tetramethoxy-14a-methyl-11,12,13,14,14a,15-
hexahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinoline (8). To a 
solution of compound 7 (67 mg, 0.16 mmol) in MeOH (2.4 mL) 
at 0 ºC was added concentrated HCl (12 M, 0.5 mL) and the 
mixture was stirred for 24 h at room temperature. At this point 
the solvent was replaced by EtOH (4.5 mL), followed by the 
sequential addition of aqueous formaldehyde (37%, 0.83 mL) 
and concentrated HCl (12 M, 0.12 mL). The reaction mixture 
was put under argon atmosphere, protected from light 
irradiation and stirred at 90 ºC during 72 h. After cooled to 
room temperature, the mixture was concentrated under 
vacuum and the residue was distributed into CH2Cl2 (10 mL) 
and 2 M aqueous solution of NaOH (5 mL). The aqueous phase 
was extracted with CH2Cl2 (3 x 10 mL) and washed with brine 
(5 mL), dried over Na2SO4, and concentrated to dryness. 
Purification by flash column chromatography (7:3 hexane/(3:1 
EtOAc/EtOH with 2% NH4OH)) afforded the desired product as 
a pale yellow solid (50 mg, 74%): [α]D
20 
 52 (c 5.84, MeOH); Rf 
0.19 (7:3, hexane/(3:1 EtOAc/EtOH with 2% NH4OH)); 96:4 er 
according to chiral HPLC analysis [tR (minor) 16.69 min, tR 
(major) 18.95 min, see ESI for details]; 
1
H NMR (300 MHz, 
CDCl3) δ 7.85 (s, 2H), 7.30 (s, 1H), 7.16 (s, 1H), 4.18 (br. d, J = 
16.2 Hz, 1H), 4.12 (s, 3H), 4.12 (s, 3H), 4.08 (s, 3H), 4.06 (s, 3H), 
3.94 (br. d, J = 15.4 Hz, 1H), 3.09 (br. d, J = 15.8 Hz, 1H), 2.98 – 
2.84 (m, 2H), 2.74 – 2.58 (m, 1H), 1.91 – 1.64 (m, 6H), 1.06 (s, 
3H); 
13
C NMR (75 MHz, CDCl3) δ 148.8 (2C), 148.6 (C), 148.5 (C), 
125.9 (C), 124.8 (C), 124.2 (C), 124.1 (C), 123.8 (C), 123.4 (C), 
104.0 (CH), 103.7 (CH), 103.6 (CH), 103.2 (CH), 56.2 (CH3), 56.1 
(CH3), 52.1 (C), 51.9 (CH2), 50.3 (CH2), 40.2 (CH2), 39.7 (CH2), 
26.4 (CH2), 20.8 (CH2), 14.3 (CH3); HRMS (ESI) calcd for 
C26H32NO4 422.2331 found 422.2326. 
(ent-8). It was prepared from ent-7 (135 mg, 0.33 mmol), 
following the same procedure described for the preparation of 
8, with similar yield (196 mg, 72%) and identical 
characterization data, except for the optical rotation: [α]D
20
 
52 (c 5.81, CHCl3). 
(14aR)-10-benzyl-2,3,6,7-tetramethoxy-14a-methyl-
9,10,11,12,13,14,14a,15-octahydrodibenzo[f,h]pyrido[1,2-
b]isoquinolin-10-ium bromide (9). To a solution of 8 (362 mg, 
0.86 mmol) in dry CH2Cl2 (9.8 mL), were sequentially added 
K2CO3 (264 mg, 1.89 mmol) and benzyl bromide (114 µL, 0.95 
mmol) and the reaction mixture was stirred at 25 ºC overnight. 
Afterwards, the mixture reaction was filtrated and the organic 
layer was concentrated to dryness. The residue was purified by 
flash column chromatography (95:5 to 9:1 CHCl3/ MeOH), to 
obtain the desired product as an orange solid (508 mg, > 99%): 
[ ]D
20
 – 82.0 (c 7.34, CHCl3); Rf 0.36 (9:1 CHCl3/MeOH); 
1
H NMR 
(300 MHz, CDCl3) δ 7.88 (br s, 2H), 7.41 – 7.30 (m, 2H), 7.27 – 
7.12 (m, 2H), 7.01 (br s, 1H), 6.96 – 6.81 (m, 2H), 5.15 (br d, J = 
13.5 Hz, 2H), 4.56 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 13.0 Hz, 1H), 
4.16 (s, 6H), 4.14 – 4.07 (m, 3H), 3.99 – 3.91 (m, 3H), 3.68 (d, J 
= 18.4 Hz, 1H), 3.51 – 3.33 (m, 2H), 2.81 – 2.63 (m, 1H), 2.60 – 
2.37 (m, 1H), 2.35 – 1.93 (m, 5H), 1.84 (s, 3H);
13
C NMR (75 
MHz, CDCl3) δ 150.0 (C), 149.9 (C), 149.8 (C), 149.6 (C), 132.7 
(2CH + C), 131.0(CH), 129.4(2CH), 126.9 (C), 124.8 (C), 124.4 
(C), 124.2 (C), 122.3 (C), 122.2 (C), 118.2 (C), 104.0 (CH), 103.7 
(CH), 103.6 (CH), 103.1 (CH), 68.0 (C), 56.9 (CH3), 56.5 (CH3), 
56.3 (CH3), 56.2 (CH3), 54.9 (CH2), 54.1 (CH2), 53.5 (CH2), 37.4 
(CH2), 32.7 (CH2), 21.9 (CH3), 20.3 (CH2), 17.7(CH2); HRMS (ESI) 
cald for C33H38NO4 512.2801 found 512.2799. 
(ent-9). It was prepared from ent-8 with similar yield (112 mg, 
91 %) and identical characterization data, except for the 
optical rotation: [ ]D
20
 86.6 ( c 6.33, CHCl3). 
(9S,14aR)-9-benzyl-2,3,6,7-tetramethoxy-14a-methyl-
11,12,13,14,14a,15-hexahydro-9H-dibenzo[f,h]pyrido[1,2-
b]isoquinoline (10). In a dry two-necked round-bottom flask, 
equipped with a condenser, was added NaH (60% mineral oil 
dispersion, 188.0 mg, 7.85 mmol). The solid was washed twice 
with hexane, removing the solvent and drying the solid with 
cycles of vacuum/ Argon, before dry DMSO (8 mL) was added. 
The mixture was heated to 60 ºC during 2 h until the evolution 
of gases (H2) ceased and complete dissolution of solids was 
observed. At this point, compound 9 (224.5 mg, 0.38 mmol) 
was added and the mixture was stirred 5 h at 25 ºC, before 
being quenched with H2O (15 mL). The resulting white 
precipitate was filtrated, washed with water and dried under 
vacuum. The obtained solid was purified by flash column 
chromatography (100% CHCl3 to 99: 1 CHCl3/ i-PrOH) to obtain 
the desired product as pale yellow foam solid (102 mg, 52%): 
[ ]
D
20 – 154.5 (c 5.95, CHCl3);  Rf 0.28 (99: 1 CHCl3/ 
i
PrOH); 95:5 
er according to chiral HPLC analysis [tR (minor) 7.67 min, tR 
(major) 8.43 min, see ESI for details]; 
1
H NMR (300 MHz, CDCl3) 
δ 7.89 (s, 1H), 7.85 (s, 1H), 7.40 (s, 1H), 7.09 (s, 1H), 6.99 (ddd, 
J = 6.3, 3.7, 1.3 Hz, 1H), 6.96 – 6.86 (m, 2H), 6.63 – 6.56 (m, 
2H), 4.37 (t, J = 3.7 Hz, 1H), 4.14 (s, 3H), 4.12 (s, 3H), 4.04 (s, 
3H), 4.00 (s, 3H), 3.15 (dd, J = 13.1, 4.1 Hz, 1H), 3.07 – 2.94 (m, 
2H), 2.74 – 2.58 (m, 2H), 1.93 (d, J = 15.1 Hz, 1H), 1.78 – 1.59 
(m, 6H), 0.76 (s, 3H).
13
C NMR (75 MHz, CDCl3) δ 148.8 (C), 
148.6 (2C), 148.2 (C), 139.0 (C), 130.6(2CH), 128.7(C), 128.3 (C), 
126.7(2CH), 125.62(C), 125.6(CH), 124.1(C), 123.9(C), 123.5(C), 
104.9(CH), 104.3(CH), 104.0(CH), 103.5(CH), 60.0(CH), 
56.2(2CH3), 56.1(CH3), 56.0(CH3), 51.2(C), 46.9(CH2), 41.9(CH2), 
41.1(CH2), 40.1(CH2), 26.8(CH2), 20.9(CH2), 13.9(CH3). HRMS 
(ESI) cald for C33H38NO4 512.2801 found 512.2794. 
(ent-10). It was prepared from ent-9 with similar yield (12 mg, 
45%) and identical data as 10 except for the optical rotation: 
[ ]D
20
 155.2 (c 4.50, CHCl3). 
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